Noninvasive tests of vascular function and structure: Why and how to perform them by Fathi, R & Marwick, TH
Author’s Accepted Manuscript
Pathophysiology and Prevention of Heart Disease
in Diabetes MellitusDiabetes and heart disease;
pathophysiology and prevention
Ahmet Afşin Oktay, Halis Kaan Akturk, Kerim
Esenboğa, Fahad Javed, Nichole M. Polin, Eiman
Jahangir
PII: S0146-2806(17)30088-9
DOI: http://dx.doi.org/10.1016/j.cpcardiol.2017.05.001
Reference: YMCD349
To appear in: Current Problems in Cardiology
Cite this article as: Ahmet Afşin Oktay, Halis Kaan Akturk, Kerim Esenboğa,
Fahad Javed, Nichole M. Polin and Eiman Jahangir, Pathophysiology and
Prevention of Heart Disease in Diabetes MellitusDiabetes and heart disease;
pathophysiology and prevention, Current Problems in Cardiology,
http://dx.doi.org/10.1016/j.cpcardiol.2017.05.001
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version of
the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable form.
Please note that during the production process errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
www.elsevier.com/locate/buildenv
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus  
 
Authors: Ahmet Afşin Oktay,1 Halis Kaan Akturk,2 Kerim Esenboğa,3 Fahad Javed,1 Nichole M. Polin,1 
Eiman Jahangir4 
 
Affiliations:  1Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute; 
Ochsner Clinical School - The University of Queensland School of Medicine, New Orleans, Louisiana. 
2Barbara Davis Center for Diabetes, University of Colorado – School of Medicine, Aurora, Colorado. 
3Department of Cardiology, Ankara 29 Mayis Hospital, Ankara, Turkey. 4Department of Cardiology, 
Kaiser Permanente Santa Rosa Medical Center, Santa Rosa, California. 
 
Running Title: Diabetes and heart disease; pathophysiology and prevention 
 
Key Words: Diabetes mellitus, heart diseases, cardiovascular diseases, insulin resistance, prediabetic 
state, diabetic cardiomyopathies, coronary artery disease, hypertension, dyslipidemias, heart failure 
 
 
Disclosures: No relevant disclosures 
 
Address for correspondence:  
Ahmet Afşin Oktay, MD 
1514 Jefferson Hwy.  
New Orleans, LA, 70005, USA 
Phone: +1 (504) 842-4135  
Fax: +1 (504) 842-4465 
Email: ahmet.oktay@ochsner.org  
 
 
 
ABBREVIATIONS AND ACRONYMS: 
 
ACC = American College of Cardiology 
ACE = Angiotensin converting enzyme 
ADA = American Diabetes Association  
AGEs = Advanced glycation end products 
AHA = American Heart Association 
APOE = Apolipoprotein-E 
ARB = Angiotensin receptor blocker 
ASCVD = Atherosclerotic cardiovascular disease 
BP = Blood pressure 
CAD = Coronary artery disease 
CAN = Cardiac autonomic neuropathy 
CMP = Cardiomyopathy 
CV = Cardiovascular  
CVD = Cardiovascular disease  
DCCT = Diabetes Control and Complications Trial  
DKD = Diabetic kidney disease 
DM = Diabetes mellitus  
DPP-4 = Dipeptidyl peptidase-4 
FFA = Free fatty acid 
FHS = Framingham Heart Study 
FPG = Fasting plasma glucose  
GLP-1 = Glucagon-like peptide-1 
HbA1c = Hemoglobin A1c 
HDL-C = High-density lipoprotein cholesterol 
HF = Heart failure 
HFpEF = Heart failure with preserved ejection fraction 
HFrEF = Heart failure with reduced ejection fraction 
HTN = Hypertension 
IR = Insulin resistance 
LDL = Low-density lipoprotein 
LDL-C = Low-density lipoprotein cholesterol 
LV = Left ventricular/ventricle 
MetS = Metabolic syndrome 
MI = Myocardial infarction  
NO = Nitric oxide 
PAT = Pericardial adipose tissue 
PCSK9 = Proprotein convertase subtilisin/kexin type 9  
RAAS = Renin-angiotensin-aldosterone system 
RCT = Randomized controlled trial 
SBP = Systolic blood pressure 
SGLT-2 = Sodium-glucose cotransporter-2 
T1DM = Type 1 diabetes mellitus 
T2DM = Type 2 diabetes mellitus 
US = United States 
UKPDS = United Kingdom Prospective Diabetes Study   
VLDL-C = Very-low-density lipoprotein cholesterol 
 
 
ABSTRACT  
Diabetes mellitus (DM) has become public health problem worldwide, and it has large implications for 
cardiovascular disease (CVD). In this article, we discuss the etiology and pathophysiology of CVD in DM 
including the effects of abnormal glucose homeostasis, genetic factors, epigenetics, apoptosis, common 
pathophysiological mechanisms shared by both DM and CVD, and contributions of other comorbidities. 
We then cover the pathogenesis of both atherosclerotic disease and cardiomyopathy in relation to DM. 
Finally, we discuss the prevention of heart disease in DM with a focus on hypertension and dyslipidemia 
management, weight loss, lifestyle changes, antiplatelet therapy, and glycemic control. 
 
SCOPE OF THE PROBLEM 
The aging population and global epidemic of obesity due to dietary patterns and sedentary 
lifestyle have led to the rising burden of diabetes mellitus (DM) worldwide. Since the 1980s, the global 
prevalence of DM has more than doubled in men and increased by 60% in women.1 In the United States 
(US) the prevalence of DM among adults ranges from 12% to 14% (Figure 1). In addition, one-third of US 
adults are estimated to have pre-diabetes.2 The prevalence of DM worldwide was estimated as 6.4% in 
2010. The number of people with DM is expected to rise to almost 600 million in the next two decades 
across the world.3  
The prevalence of DM increases with advancing age in both genders. In the US, the prevalence 
of DM is 5% in individuals aged <45 years and increases to 33% in those ≥65 years of age.2 Men usually 
have a slightly higher prevalence of DM compared to women.4 DM has a significant association with 
ethnicity. It is more commonly seen in non-Hispanic blacks (15.4%) and Mexican-Americans (11.6%) 
compared to whites (8.6%).5 It is estimated that more than one-third of US adults with DM are unaware 
of their diagnosis (Figure 1).2  
DM has long been recognized as a major risk factor for cardiovascular disease (CVD). Also, DM is 
associated with clustering of other major CVD risk factors such as hyperlipidemia, hypertension (HTN) 
and obesity. Thanks to improvements in diagnostic and therapeutic modalities and health care delivery, 
cardiovascular (CV) morbidity and mortality has declined in the general population over the past 
decades. Similar trends were observed in diabetic individuals as well.6, 7 However, despite these 
improvements, DM continues to be a cause of CV morbidity and mortality in all age groups and both 
sexes.8 A report from the “early period” (1950-1975) of Framingham Heart Study (FHS) demonstrated 4-
fold increased risk of CVD in diabetic individuals compared to non-diabetics. However, this excess risk 
decreased to 3-fold in the “later period” of the study (1975-2005).9 A large population-based study 
conducted between 1997 and 2002 demonstrated that patients with DM requiring glucose-lowering 
agents exhibited a CV risk equivalent to non-diabetics with prior myocardial infarction (MI).10 More 
specifically, DM increases the risk of each component of CVD such as coronary artery disease (CAD),11 
heart failure (HF), atrial fibrillation,12 and stroke.13 Therefore, CVD remains the leading cause of death in 
individuals with DM.  Over 68% of diabetic individuals >65 years of age die from a form of heart disease.6 
On average, a 50-year-old person with DM dies six years earlier compared to a counterpart without 
DM.14  
The strong relation between DM and CVD has been a major topic of interest among clinicians 
and researchers. The ever growing importance of this relationship is represented by the fact that within 
the past decade many major society guidelines and scientific statements have been dedicated to 
prevention or management of CVD in individuals with DM. 15–19 
 In this review, we will explore the current state of knowledge linking DM and heart disease with 
a focus on pathophysiology and prevention. 
CLASSIFICATION OF DIABETES MELLITUS 
 DM is defined as the complex dysregulation of glucose metabolism secondary to deficiencies in 
insulin secretion, desensitization of the insulin receptors, or a combination of both, which results in 
chronic hyperglycemia and subsequently leads to acute and chronic complications.20 According to the 
American Diabetes Association (ADA), DM can be diagnosed by either fasting plasma glucose (FPG), 2-
hour plasma glucose after oral glucose tolerance test and hemoglobin A1C (HbA1c).21 Based on the 
etiology, DM is categorized into four main groups: type 1 DM (T1DM), type 2 DM (T2DM), ‘other specific 
types’ of DM, and gestational DM.22 
 T1DM is characterized by progressive insulin deficiency due to autoimmune destruction of 
pancreatic β-cells. Although T1DM may occur at any age, it typically affects young and slim individuals 
and present with an abrupt onset. T2DM, which comprises over 90% of DM among adults, is 
characterized by a combination of insulin resistance (IR) and pancreatic β-cell dysfunction in association 
with obesity and metabolic syndrome (MetS). T2DM is a progressive disease, and it is almost always 
preceded by impairment of glucose metabolism referred as pre-diabetes. Impaired glucose tolerance 
and impaired fasting glucose are the main manifestations of pre-diabetes.16 
 The clear majority of data on the relationship between DM and CVD derives from population 
studies and clinical trials on cohorts of either patients with T2DM exclusively or all DM patients without 
distinction of DM type (presumably, the majority is T2DM because of its abundance). Therefore, data on 
the relationship of CVD and DM types other than T2DM remains limited.  
ETIOLOGY AND PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS  
 Studies in the past decades have shed light into the pathophysiologic link between DM and CVD. 
A complex interplay between numerous pathophysiologic mechanisms underlies the increased risk of 
CVD in patients with DM. These mechanisms can be grouped as follows. 1) CV effects of derangements 
in glucose homeostasis, 2) shared common mechanisms underlying the pathogenesis of both DM and 
CVD, 3) contribution of other CV risk factors (such as HTN and hyperlipidemia) that commonly coexist 
with DM, 4) genetic and 5) epigenetic factors and 6) apoptosis. 
Cardiovascular Effects of Abnormal Glucose Homeostasis 
IR is the central defect in the natural history of MetS and T2DM. Classically, it refers to the 
inability of insulin to carry on its metabolic actions at the cellular level. 23 IR and consequent 
compensatory hyperinsulinemia may precede the diagnosis of T2DM by 10-20 years.24 Epidemiologic 
data have demonstrated that IR is associated with the presence and progression of CAD even in the 
absence of overt DM.25,26 HF is a well-known insulin resistant state, and IR significantly affects prognosis 
in HF.27 Moreover, HF contributes to IR. For instance, in patients with advanced HF, hemodynamic 
recovery after ventricular assist device placement have been shown to result in improvements in 
systemic and cardiac insulin sensitivity, glucose homeostasis and reduction of toxic lipid products.28 
Impaired fasting glucose has been shown to predict future CAD in some prospective 
epidemiological studies, such as the Heinz Nixdorf Recall Study.29  However, in some other studies (such 
as FHS), this association became non-significant after adjustment for confounders such as obesity.30 
Emerging data suggests that not only the baseline status but also the dynamic nature of glucose 
homeostasis abnormalities contribute to the risk of CAD. For example, a recent epidemiologic study 
from Korea showed that progression from insulin resistant state to T2DM is an independent predictor of 
the development of CAD (Figure 2).31 These results indicate the importance of preventing progression to 
overt DM from MetS. 
 IR affects tissues and pathways in a selective manner, and this contributes to the development 
of T2DM and related complications. In simple terms, certain tissues or pathways may retain their insulin 
sensitivity even in insulin resistant states. For instance, in individuals with T2DM, insulin fails to suppress 
glucose production but continues to promote synthesis of lipids in the liver.32 Another example for 
selective IR is the pathogenesis of atherosclerosis. Insulin is known to activate both anti-atherosclerotic 
and atherosclerotic mechanisms under normal physiologic conditions. It has been suggested that 
selective IR of anti-atherosclerotic pathways in the vasculature play a role in atherosclerosis and 
microvascular complications in patients with T2DM.32,33  
Shared Common Mechanisms 
Renin-angiotensin-aldosterone system (RAAS) is an enzymatic cascade which is involved in a 
wide variety of physiologic mechanisms in the human body. Over-activation of RAAS has been 
associated with obesity, HTN, IR, T2DM, left ventricular (LV) remodeling and HF.34,35 There is a growing 
body of evidence that over-activation of RAAS constitutes a pathophysiologic link between obesity, DM, 
and CVD. RAAS blockade is an essential component of HTN and HF management. Moreover, RAAS 
blockade has been associated with increased pancreatic insulin secretion and decreased glucose 
intolerance,36 improved insulin sensitivity37, and prevention of development of DM.38 
Inflammation triggered by obesity is a central component of the association between obesity, 
T2DM, CAD and HF.39,40 The expanding adipose tissue in obese individuals recruits immune cells such as 
macrophages, B-cells, and T-cells. The overproduction of proinflammatory cytokines by these immune 
cells result in obesity-associated inflammation.41,42 This chronic low-grade inflammation promotes the 
development of IR and T2DM.42,43 Similarly, chronic inflammation (local or systemic) plays a critical role 
in the pathogenesis of endothelial dysfunction, atherosclerosis, CAD and HF.40,44,45 
Recent studies have revealed the significant influence of vasopressin in the pathogenesis of DM 
and CVD. Vasopressin is a small peptide with a short plasma half-life. Vasopressin activity is more 
reliably measured using a clinic surrogate marker, copeptin, which is the C-terminal portion of the 
vasopressin precursor and considered to be a more stable molecule.46,47 Elevated plasma copeptin levels 
have been linked to DM,48 abdominal obesity, renal disease49 and CVD.50 Furthermore, elevated 
copeptin was found to be an independent predictor of CV morbidity and mortality in patients with 
DM.46,51  These findings suggest that vasopressin activity, measured with copeptin, is a promising marker 
for identifying individuals who are at risk for DM and its CV complications. Moreover, vasopressin 
system may be a novel therapeutic target for prevention of heart disease in patients with DM.46    
Contribution of Other Comorbidities 
Adiposity, its regional distribution, and fat quality play a significant role in the development of 
DM and CVD.52 Both subcutaneous and visceral adipose tissue are independent predictors of 
cardiometabolic risk, though the latter is considered to have a more significant relation with DM and 
heart disease.53 In the recent decades, adiposity surrounding the heart, referred as pericardial adipose 
tissue (PAT), has emerged as a strong, independent risk factor for LV hypertrophy, CAD, HF, atrial 
fibrillation, and CV mortality.54–58  Several distinct mechanisms, which usually derive from the anatomical 
contiguity of PAT with the myocardium and major coronary arteries, are involved in the link between 
increased PAT and pathogenesis of CVD. These mechanisms are endothelial dysfunction, increased 
fibrosis, fatty infiltration of the myocardium, oxidative stress, paracrine and proinflammatory effects of 
adipokines secreted from pericardial fat.59,60 Epidemiologic studies have demonstrated that individuals 
with pre-diabetes and DM have a significantly higher volume of PAT compared to those with 
normoglycemia.61 Moreover, the thickness of PAT significantly correlates with FPG, IR, HbA1c, systolic 
blood pressure (SBP), triglyceride levels and risk of CAD in patients with DM.62 These findings supports 
the potential role of PAT in the pathophysiologic link between DM and CVD.63  
 HTN effects the majority of patients with DM, and its prevalence varies depending on age, 
gender, ethnicity and type of DM.21 The common occurrence of HTN and DM in the same individual is 
explained by common risk factors and shared pathophysiologic mechanisms such as IR, endothelial 
dysfunction, oxidative stress, systemic inflammation and over-activation of RAAS and sympathetic 
nervous system.64,65 Coexistent HTN and DM, especially if blood pressure (BP) is uncontrolled, 
dramatically increases the risk of CV morbidity and mortality.66  Limited data exists on the 
pathophysiological basis of excessive CVD risk in coexistent HTN and DM. One potential explanation 
comes from a recent study on mice models which demonstrated an increase in susceptibility to HTN-
induced hypertrophic remodeling as a consequence of DM.67    
 Dyslipidemia is a major contributor to CVD risk in patients with DM. The lipid patterns in 
patients with well-controlled T1DM usually does not show a significant difference from the general 
population. However, patients with T2DM and uncontrolled T1DM tend to have elevated triglycerides, 
decreased high-density lipoprotein cholesterol (HDL-C), smaller low-density lipoprotein (LDL) particles 
with normal or increased LDL cholesterol (LDL-C) levels.68,69 Hypertriglyceridemia is the hallmark finding 
of diabetic dyslipidemia mainly due to increased lipolysis. IR increases production of very LDL-C (VLDL-C) 
by the liver and chylomicrons by the intestines. IR also leads to decreased metabolism of VLDL-C and 
chylomicrons due to impairment of the function of lipoprotein lipase enzyme.68,70 VLDL-C and 
chylomicrons are rich in triglycerides, and they transfer triglycerides to LDL-C and HDL-C, respectively. 
Triglyceride-rich HDL-C particles tend to have a shorter half-life which leads to lower HDL-C levels. Also, 
DM cause alterations in the protein moiety of HDL-C which leads to impairment of vasoprotective role of 
HDL-C.71 Additionally, triglyceride-rich LDL-C particles tend to be small and dense, which is the more 
atherogenic form compared to larger LDL-C particles.68,72 
Autonomic nervous system dysfunction is common in patients with DM. Cardiac autonomic 
neuropathy (CAN) has been shown to cause CVD in patients with DM. In fact, numerous studies have 
confirmed the relationship of CAN with LV remodeling,73 LV systolic and diastolic dysfunction,74, 75 
myocardial ischemia,76 ischemic stroke,77 CV events78 and mortality (Figure 3).79 The primary 
determinants of CAN are the duration of DM and severity of hyperglycemia.80 It has been suggested that 
sympathetic overactivation occurs in the earlier stages of diabetic CAN because of predominant 
parasympathetic denervation.81 At the later stages, CAN results in sympathetic dysregulation as well. 
CAN may present with resting tachycardia, impaired heart rate variability, blunted heart rate response 
to exercise, abnormal BP regulation and orthostatic hypotension.82  
Genetic Factors  
Several genetic polymorphisms have been identified to influence the progression and prognosis 
of CVD in DM. Only some of these genetic associations will be discussed here. 
 Variations in haptoglobin genotypes are well-established genetic risk factors for CVD in patients 
with DM. Haptoglobin is an acute phase protein which binds to free hemoglobin and prevents 
hemoglobin-induced oxidative tissue damage.17 In humans, three different haptoglobin genotypes 
(haptoglobin 1-1, haptoglobin 1-2, haptoglobin 2-2) exist, and the product of each genotype has a 
different antioxidant capacity. In patients with T1DM, haptoglobin 2-2 genotype was associated with 2-
fold increased risk of CAD compared to haptoglobin 1-1 genotype.83,84 Another study of two large 
independent cohorts revealed that individuals with HbA1c level ≥6.5% and haptoglobin 2-2 genotype are 
at >10-fold increased the risk of CAD compared to those with HbA1c level <6.5% and haptoglobin 1-1 
genotype (Figure 4).85    
APOE (Apolipoprotein E) gene has been studied extensively in case-control studies including 
individuals with DM and CAD. APOE acts as a ligand and stabilizes and solubilizes circulating lipoproteins. 
Some variants of APOE gene have been shown to strongly influence the risk of development of DM and 
CAD (~2-fold increased risk for CAD and DM).86 
 Genome-wide association studies in the recent decade have provided further evidence for the 
genetic basis of the relationship between DM and CVD. For instance, genetic variations that reduce the 
expression of IRS1 gene were found to be associated with increased risk of IR, DM, and CAD.87–89 The 
product of this gene, insulin receptor substrate-1, plays a role in intracellular insulin signaling. 
Interestingly, the same genetic variants were linked to lower body-fat percentage in men.87  Another 
recent study identified ten different genetic loci that modify the risk of both DM and CAD.90 It should be 
noted that the clinical significance of genome-wide association study identified genetic variants remains 
unclear because of the subtle contribution from each genetic variant in the overall disease risk. 
 A recent study examined the cardiometabolic effects of a cluster of 11 genetic variants which 
are known to be linked to indices of IR from prior studies. The analysis demonstrated that the group of 
these 11 common genetic variants was associated “lipodystrophy-like” phenotype including higher 
visceral to subcutaneous adipose tissue, lower BMI, and predisposition to MetS, T2DM, and CAD.91 
Epigenetics 
 Epigenetics is defined as heritable modifications in the genome without any changes in the 
coding sequence.92 Epigenetic mechanisms influence activity of the genes in the genome through 
several mechanisms such as DNA methylation, histone modifications, non-coding RNA and post-
translational changes.93 Epigenetic mechanisms constitute a significant link between environmental 
exposure and alterations in gene activity. Several epigenetic factors have been shown to play a role in 
pancreatic β-cell dysfunction and development of DM.94–96 There is also growing evidence that 
epigenetic changes in CV cells induced by chronic hyperglycemia, inflammation and oxidative stress 
significantly contribute to the increased risk of vascular dysfunction and CVD in patients with DM.97,98 
The pertinent epigenetic modifications  are believed to underlie diabetes-related ‘metabolic memory’ 
which refers to the fact that prolonged hyperglycemia in patients with DM results in diabetic 
complications even after establishment of normoglycemia with lifestyle modifications and 
pharmaceutical agents.99 Recent studies on animal models suggested that epigenetic modification 
enzymes such as histone acetylases, deacetylases, or DNA demethylases might emerge as novel targets 
for reversal of epigenetic changes induced by DM and thus prevention of diabetic complications.93,100 
Apoptosis 
Apoptosis, the process of programmed cell death, has been implicated in development of 
diabetic cardiomyopathy (CMP),101 as well as other CVDs such as atherosclerosis, ischemic heart disease 
and HF.102,103 Individuals with DM, compared with non-diabetics, were found to have 85-fold, 61-fold, 
and 26-fold increase in apoptosis of cardiomyocytes, endothelial cells and fibroblasts, respectively.104 
Autophagy, the lysosomal process that degrades and recycles cellular proteins and organelles, is an 
essential part of cellular homeostasis. Suppression or prolonged activation have been linked to 
increased apoptosis.103 Recent studies have identified dysregulation of autophagy as a key component of 
DM-induced apoptosis of the cardiomyocytes.105, 106  The cardiomyocyte autophagy patterns 
demonstrate marked differences between patients with T1DM and T2DM. A recent study in animal 
models showed that T1DM is associated with over-activation of autophagy while T2DM is related with 
suppression.107 
PATHOGENESIS OF VASCULOPATHY 
Endothelial Dysfunction 
  Endothelial dysfunction is a hallmark finding implicated in the development of heart disease due 
to DM. Abnormalities in the metabolism of nitric oxide (NO), an important endothelial cell mediator, 
appear to play a significant role in the development of endothelial dysfunction, atherosclerosis, and HTN 
in individuals with IR and DM. Under normal physiologic circumstances, NO induces vasorelaxation and 
activates anti-atherosclerotic and anti-inflammatory pathways.23 However, IR and DM impair release of 
NO from the endothelial cells, which reduces NO-dependent vasodilation and increases leukocyte 
adhesion to the endothelium.108, 109 Furthermore, decreased NO release can result in activation of 
platelet adhesion and abnormalities in endothelial layer integrity.110 Interestingly, a recent study on 
diabetic mice models revealed that activation of NO synthesis using a special peptide called cavNOxin 
decreased the risk of atherosclerosis due to DM.111 Evidence suggest that hyperglycemia can induce 
oxidative stress in the endothelium due to over-production of reactive oxygen species.112 And the 
oxidative stress triggers several cascades which play a role in local inflammation and endothelial 
dysfunction. 
Microangiopathy 
 Persistent endothelial dysfunction and several other pathophysiological mechanisms lead to 
structural changes in the coronary vascular system such as microangiopathy and atherosclerosis. 
Microangiopathy -usually defined as the vasculopathy of small arteries, arterioles, capillaries, and 
venules- is a common finding in the myocardium of patients with DM. The cardiac microangiopathy due 
to DM is characterized by thickening of the capillary membranes, perivascular fibrosis, and 
microaneurysms, spasm, and spiral deformation of microvessels.113 Moreover, DM leads to a reduction 
of capillary density, apoptosis of endothelial cells and interstitial fibrosis secondary to the down-
regulated expression of vascular endothelial growth factor.114 Coronary microvascular dysfunction, even 
in the absence of obstructive CAD, has been shown to predict CV events in patients with DM.115  
 
Atherosclerosis 
 Atherosclerosis is the most common cause of CAD in diabetic and non-diabetic individuals. 
Macrophages constitute an essential component of the link between IR, DM, and atherosclerosis. For 
instance, the insulin-resistant macrophages increase expression of scavenger receptors which internalize 
oxidized LDL-C, and this process promotes the formation of foam cells and subsequent development of 
fatty streaks.16 These fatty streaks transform into atherosclerotic plaques over many years. 
Atherosclerotic plaques in patients with DM tend to have a higher content of lipids and infiltration of 
macrophages, compared to those in non-diabetic individuals.116 In the presence of local and systemic 
inflammation, atherosclerotic plaque becomes unstable which increases the risk for rupture and 
thrombus formation.  
Pro-thrombotic State 
 DM contributes to the risk of CV events by inducing a pro-thrombotic state. In fact, IR and 
hyperglycemia result in reduced tissue plasminogen activator, and increased levels of fibrinogen, factor 
VII and XII and plasminogen-activator-inhibitor-1.117 DM can cause platelet hyperreactivity due to 
alterations in platelet activation, adhesion, and aggregation. Moreover, hyperglycemia contributes to 
the pro-thrombotic state by expression of glycoproteins (IIb and IIb/IIIa) and P-selectin and activation of 
the P2Y12 pathways.16 Among patients presenting with unstable angina, those with DM were shown to 
have higher frequency of plaque ulceration and intracoronary thrombus formation compared to those 
without DM.118 
PATHOGENESIS OF HEART FAILURE 
 HF has a heterogeneous etiology in individuals with DM. The most common causes of HF in 
diabetic individuals are; myocardial ischemia, HTN, diabetic CMP and renal dysfunction.119  
CAD affects patients with DM at earlier ages, and these patients tend to have multivessel CAD 
with the involvement of distal coronary segments. Moreover, compared to those without DM, patients 
with DM develop fewer collateral vessels in response to ischemia120 and have larger infarct size and 
higher risk of developing HF following an MI.121,122 Studies in animal models have demonstrated that the 
tendency for larger infarct size in patients with DM derives from impairment of cytoprotective 
mechanisms and increased susceptibility to ischemia/reperfusion injury.113,122,123 It appears that duration 
of a diabetic state and plasma level of insulin are some of the major determinants of myocardial 
tolerance against infarction in patients with DM.113  
 Coexistence of HTN and DM significantly increases the risk of development of HF. In fact, a 
meta-analysis of subjects included in clinical trials demonstrated that presence versus absence of DM in 
hypertensive individuals increased the risk of HF by more than 4-folds.124 
Diabetic Cardiomyopathy 
 DM and IR can also promote the development of CMP and HF independent of traditional risk 
factors such as CAD and HTN. This unique form of CMP is termed as diabetic CMP (Figure 5). Female 
patients with DM appear to be more susceptible to this type of CMP.125 DM usually coexist with other HF 
risk factors such as HTN, CAD, and renal disease. Therefore, the burden of “pure” diabetic CMP is not as 
high as the CMP of heterogeneous etiology. However, diabetic CMP has been a hot topic of research 
since its first description more than four decades ago.126 Even though HF in diabetic individuals is usually 
caused by multiple risk factors, the concept of diabetic CMP carries clinical significance since it 
emphasizes the influence of DM and IR on the cardiac structure and function. 
 Per the traditional concept, diabetic CMP is a progressive syndrome initiated with subclinical 
structural and functional abnormalities, which are followed by diastolic HF, an intermediate form 
between subclinical abnormalities and the “true” manifestation of the disease; LV systolic dysfunction. 
Consistently, LV systolic dysfunction has been considered as one of the major diagnostic criteria for 
diabetic CMP. However, the new line of evidence has challenged some parts of these assumptions. Most 
importantly, HF with preserved ejection fraction (HFpEF) is now more widely accepted as a distinct 
phenotype of diabetic CMP, rather than being an intermediate form between risk factors and HF with 
reduced ejection fraction (HFrEF).127 These two different phenotypes (HFpEF vs. HFrEF) of diabetic CMP 
are mostly underlain by various pathophysiologic mechanisms and the transition from HFpEF to HFrEF 
does not occur as commonly as we once thought. The current concepts on the distinct phenotypes of 
diabetic CMP were recently reviewed in detail by others.127  
 In diabetic CMP with HFpEF phenotype, the LV is usually hypertrophied and stiff with normal LV 
volume. At the cellular level, cardiomyocytes appear hypertrophied with normal structure of the 
sarcomere accompanied by increased collagen deposition in the interstitial space. Diabetic CMP with 
HFrEF phenotype is usually associated with increased LV volume due to dilatation. At the cellular level, 
cardiomyocytes appear to be damaged with loss of sarcomeres and replacement of some 
cardiomyocytes with fibrosis.127 
 The impact of DM and IR on the cardiac morphology and function has been studied extensively. 
In the FHS, higher levels of IR and worsening levels of glucose intolerance were correlated with 
increased LV mass and wall thickness.128 A recent longitudinal study with a long follow-up period (25 
years) revealed that DM and poor glycemic control have a cumulative effect on adverse LV remodeling 
and subclinical LV dysfunction.129  Studies on population-based cohorts have indicated that DM (mostly 
T2DM) and IR are linked to concentric LV remodeling and hypertrophy.130,131 DM shows significant 
association with diastolic dysfunction. In fact, diastolic dysfunction is the most common 
echocardiographic abnormality observed in patients with T1DM and T2DM.113 The frequency of diastolic 
dysfunction in patients with DM ranges between 20% to 75% depending on the criteria used and the 
population studied.128,132 Furthermore, diastolic dysfunction is observed in individuals with DM even in 
the absence of LV hypertrophy, which suggests that hypertrophy is not an absolute necessity for DM-
induced ventricular dysfunction. Systolic LV dysfunction is also commonly seen in patients with DM, 
although its frequency appears to be lower compared to diastolic dysfunction.113 Numerous studies have 
confirmed the high rate of subclinical LV systolic dysfunction (evaluated by strain imaging) in 
asymptomatic patients with DM.133,134 It should be noted that adverse LV remodeling and subclinical 
myocardial dysfunction are important predictors of future CV morbidity and mortality, including 
HF.135,136  
 At the tissue and cellular level, a complex interaction between numerous pathophysiologic 
mechanisms plays a role in the development of diabetic CMP. These mechanisms include impaired 
myocardial insulin signaling and calcium homeostasis, abnormal coronary microcirculation, endoplasmic 
reticulum stress, autonomic dysfunction, activation of RAAS, oxidative stress and maladaptive immune 
responses.125 
 Myocardial cells in diabetic individuals demonstrate enhanced free fatty acid (FFA) uptake due 
to the higher availability of FFAs and IR-mediated impairment in myocardial glucose metabolism.24 This 
enhanced uptake subsequently leads to the accumulation of triglycerides in myocytes and promotes 
lipotoxicity, oxidative stress, mitochondrial dysfunction and apoptosis.137, 138 In diabetic hearts, the 
energy metabolism shifts from the utilization of glucose to FFA. This alteration results in reduced 
myocardial efficiency due to the significantly higher oxygen consumption required for FFA oxidation.139 
 DM impairs the contractile force of individual cardiomyocytes secondary to changes in the 
structure and function of myofibrils.24 Moreover, DM induces perturbation in the function of the 
cardiomyocyte endoplasmic reticulum which is the primary organelle for handling intracellular calcium. 
The alterations in calcium homeostasis subsequently lead to contractile dysfunction.140  
 Hyperglycemia induces the formation of advanced glycation end products (AGEs) due to the 
nonenzymatic glycation and oxidation of proteins and lipids. The accumulation of AGEs in the 
myocardium and vascular wall reduces collagen turnover due to cross-linking and consequently leads to 
myocardial fibrosis and vascular stiffness, respectively.141,142 AGEs also bind to the receptors on cellular 
membrane and activate several mechanisms in inflammation and fibrosis.143 A soluble receptor found in 
the serum binds to the AGEs and inhibit their pro-inflammatory and pro-fibrotic activity. Unsurprisingly, 
lower levels of circulating soluble receptors for AGEs predict incident HF in patients with DM.144 DM also 
induces several other pathways that are involved in the production of oxygen-derived oxidants. DM-
induced oxidative stress exerts several harmful effects by causing protein and DNA damage, interfering 
NO production and modulation of intracellular signaling pathways.24  
PREVENTION OF HEART DISEASE IN DIABETES MELLITUS 
 CVD remains the leading cause of morbidity and mortality in patients with DM. Therefore, 
prevention of CVD is a primary goal in the management of DM and associated co-morbidities. Major 
components of CVD prevention in patients with DM will be discussed here. 
Management of HTN  
HTN, defined as a sustained BP >140/90 mmHg, is a leading modifiable risk factor for CVD.21 
Coexistent DM and HTN poses a dual threat in regards to CV risk. Data from the FHS suggested that 
much of the excess risk of CVD events and death in patients with DM can be attributed to HTN.66 Thus, 
BP control is an essential component of the management of DM, to decrease the risk of CVD, diabetic 
nephropathy and other diabetic complications. It should be noted that BP control in diabetic patients 
can be challenging and it often requires a multidisciplinary approach for optimal results.64  
Many randomized control trials (RCTs) have confirmed that BP control is an effective method for 
prevention of complications in diabetic individuals. In the United Kingdom Prospective Diabetes Study 
(UKPDS) (n=4801, mean follow-up=8.4 years), each 10% reduction of SBP in diabetic individuals was 
associated 12% lower risk of acute MI, HF, and all-cause mortality.145 Similarly, a recent meta-analysis of 
40 trials with a combined sample size of >100,000 individuals found that reduction of SBP in patients 
with T2DM results in significantly lower risk of CV events, CAD, stroke, albuminuria, retinopathy, and 
mortality.146 
Optimal BP goals in general and diabetic population are still actively debated, and there exists 
some variation among guidelines in regards to target BP levels in patients with DM (Table 1). The Eighth 
Joint National Committee and the ADA recommend a target SBP of <140 mmHg and diastolic BP of <90 
mmHg of in adults with DM, regardless of age.21,147 The ACCORD-BP (Action to Control Cardiovascular 
Risk in Diabetes-Blood Pressure) trial examined the effects of tight BP control in T2DM patients with 
increased CV risk.148 The investigators did not find any significant difference between standard BP 
control (targeting SBP of <140mmHg) and tight BP control (targeting SBP of <120mmHg) strategies in 
regards to the primary outcome which was defined as a composite of nonfatal or fatal CVD events. Tight 
BP control predicted a small reduction in the risk of ischemic stroke but an increased risk of adverse 
events secondary to antihypertensive therapy.  The recent Systolic Blood Pressure Intervention Trial 
(SPRINT) demonstrated a small but statistically significant reduction in the risk of CVD events and 
mortality with intensive BP control (target SBP of <120 mmHg) compared to standard BP control (target 
SBP of 140 mmHg) in hypertensive individuals with increased CVD risk. It should be noted that results of 
the SPRINT may not apply to diabetic individuals since DM was an exclusion criterion in the SPRINT.  
DM and HTN share multiple common risk factors, and this provides a unique opportunity for 
prevention or management of DM and HTN with similar lifestyle modifications.64 The ADA recommends 
the following lifestyle changes in diabetic individuals with a BP >120/80 mmHg: 1) weight loss with 
calorie restriction, if overweight or obese; 2) increased physical activity; 3) a Dietary Approaches to Stop 
Hypertension-style diet with restriction of sodium intake (2300mg/day); 4) increasing consumption of 
fruits, vegetables, nuts, and low-fat dairy products (2–3 servings per day); and 5) avoiding excessive 
alcohol consumption.21  
Per the current guidelines angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs), calcium channel blockers and thiazide-type diuretics are the effective first-line 
antihypertensive agents in patients with DM.21,147 RCTs have not consistently favored one of these 
antihypertensives over another in individuals with DM.149 Making an appropriate choice of 
antihypertensive medication regimen in patients with DM require consideration of several other factors 
such as race, age and co-morbidities such as albuminuria, chronic kidney disease, CAD, HF, etc.64  
Dyslipidemia and Lipid-lowering Medications 
Dyslipidemia is a major contributor to the increased CVD risk in patients with DM.150 The ADA 
recommends obtaining a lipid profile at the time of diagnosis and at least every five years after that in 
diabetic adults. Routine screening is not recommended for diabetics over the age of 75 years since there 
is limited data regarding the benefits of statin therapy in this age group.21  
The beneficial effects of statins on primary and secondary prevention of atherosclerotic CVD 
(ASCVD) were demonstrated by subgroup analyses of diabetic patients in large RCTs151–153 or specific 
trials in diabetic patient populations.154,155 A meta-analysis of 14 RCTs with data from over 18,000 
diabetic patients demonstrated that each mmol/L (39 mg/dL) reduction in LDL-C with use of a statin was 
associated with 21% reduction in major vascular events, 13% reduction in vascular mortality and 9% 
reduction in all-cause mortality.156 
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for 
the treatment of hyperlipidemia defined DM as one of the four major statin benefit groups.157 According 
to these guidelines, all diabetic adults (aged 40 to 75 years) with LDL-C of 70-189 mg/dL and no known 
ASCVD should be treated with at least a moderate intensity statin and those with an estimated 10-year 
ASCVD risk score ≥7.5% should be treated with a high-intensity statin. The recommendations of ADA on 
the treatment of dyslipidemia have been consistent with the recommendations of 2013 ACC/AHA 
guidelines (Table 2).21  
Several studies have raised a concern regarding a small but statistically significant increase in the 
risk of incident DM with the use of statins, particularly in older adults.158 A meta-analysis of 13 studies 
with a combined sample size above 91,000 and a mean follow-up period of four years found a 9% 
increase in the risk of incident DM with the use of statins.159 Overall, one additional patient developed 
DM for every 255 patients treated with a statin for four years. In another meta-analysis of five statin 
trials with over 32,000 participants demonstrated a slightly higher risk of incident DM with high-intensity 
statins compared to moderate intensity statins.160 Nevertheless, CV event reduction benefits of statins 
far outweigh the risk of new-onset DM even in individuals at the highest risk for DM.21  
The efficacy of non-statin lipid lowering agents (ezetimibe, niacin, fibrates) and their 
combination with a statin have not been well-established in patients with DM. Therefore, these agents 
are not considered as a first-line therapy for dyslipidemia in patients with DM. The results of IMProved 
Reduction of Outcomes: Vytorin Efﬁcacy International Trial (IMPROVE-IT) suggested that combination of 
ezetimibe with a moderate intensity therapy can be considered for secondary prevention of CV events in 
patients with DM and a history of acute coronary syndromes if they are intolerant to high-intensity 
statin therapy.161  
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, monoclonal antibodies 
targeting the PCSK9 protein, have recently emerged as a breakthrough in the management of 
hyperlipidemia.162 Alirocumab and evolocumab (PCSK9 inhibitors in the market) can result in up to 60% 
reduction in LDL-C levels on top of a baseline statin therapy.163,164 A meta-analysis of three RCTs 
demonstrated that, compared to placebo, evolocumab therapy in patients with T2DM reduces LDL-C 
>60%, similar to the reduction in patients without T2DM.165 PCSK9 inhibitors may be reasonable as 
adjunctive therapy in diabetic patients who are at risk for ASCVD and intolerant to statins or in need of 
further lowering of LDL-C despite maximally tolerated statin therapy.21  
Obesity and Weight Loss 
Overweight and obesity play a vital role in the development of T2DM and other major CV risk 
factors such as HTN and dyslipidemia. Moreover, overweight and obesity can independently induce 
alterations in the cardiac structure and function and lead to a variety of CVD, such as HF, CAD, stroke, 
and atrial fibrillation.6,166 Therefore, purposeful weight reduction, achieved via diet, exercise or bariatric 
surgery, is an important part of prevention efforts in individuals with T2DM or at risk for T2DM. 
Studies have consistently demonstrated that weight loss can delay progression from pre-
diabetes to T2DM,167,168 improve glycemic control and insulin sensitivity, and reduce the need for 
antidiabetics in patients with T2DM.169–171 Intentional weight loss can provide favorable effects on BP in 
diabetic and non-diabetic individuals.168,172,173 Weight loss also leads to a significant improvement in HDL 
and triglyceride profiles and a modest decline in LDL-C.172,174 
Despite the significant impact of weight loss on CV risk factors, the role of weight loss in 
prevention CVD in diabetic individuals remains not well-established. The Look AHEAD (Action for Health 
in Diabetes) trial was the first large-scale randomized trial examining the impact of lifestyle 
interventions on weight and CV outcomes in overweight or obese adults with T2DM (n=5145).172,175 The 
study, after a median follow-up of 9.6 years, did not reveal any significant reduction in the CV events 
despite a significant improvement in weight, HbA1c, and other CV risk factors.  A recent post hoc 
analysis of The Look AHEAD trial showed that the magnitude of weight loss in patients with T2DM was a 
determinant of the risk of future CVD.176 In fact, the study participants in the intensive lifestyle 
intervention group who lost at least 10% of their body weight had ~20% lower risk of CV events. 
The ADA recommends prescription of diet, physical activity and behavioral therapy with the goal 
of 5% (ideally ≥7%) weight loss for overweight or obese individuals with T2DM.21 To achieve this goal, 
patients should be instructed about 500-750 kcal/day energy deficit. Enrollment in weight management 
programs can help with short-term and sustained weight loss. Whenever possible from a clinical 
standpoint, physicians should choose antidiabetic agents which are weight neutral or promote weight 
loss (Table 3).  
The prevalence of severe obesity (body mass index ≥40 kg/m2) has been rising and now affects 
almost 8% of the US adults.177 In the recent decades, bariatric surgeries have emerged as effective 
treatment options for severely obese individuals, particularly if performed as a part of a comprehensive 
weight loss management strategy.21 Observational and non-randomized studies have demonstrated that 
weight loss with bariatric surgeries can lead to better glucose control, diabetes remission, and improved 
LV structure and function and a lower rate of CV events.178,179 However, we still lack evidence from 
randomized trials with large sample sizes. The Swedish Obese Subjects (SOS), which included 2010 
obese subjects who underwent a bariatric surgery and 2037 contemporaneously matched obese 
controls, found the significantly lower rate of CV events in the bariatric surgery group.180 Similarly, a 
meta-analysis of 14 observation studies with >29,000 patients who underwent bariatric surgery and 
>166,000 nonsurgical controls demonstrated a significant reduction in CV events in response to bariatric 
surgery.181      
Lifestyle Changes 
Physical activity can delay the progression from pre-diabetes to diabetes, improve glycemic 
control and decrease the risk of CV complications in patients with DM.16,182,183 Studies in the general 
population have demonstrated reduced risk of all-cause and CV mortality even with leisure time running 
(5-10 minutes per day).184 Compared with no exercise, any exercise such as walking (as little as 2 
hours/week) and physical activity for occupation and leisure can provide substantial benefits on the CV 
risk in patients with DM.185,186 Studies have suggested that patients with diabetes benefit more from 
combined aerobic and resistance training programs compared to either modality alone.187 
The ADA recommends 1) limiting sedentary lifestyle, 2) ≥150 min/week moderate-intensity 
aerobic physical activity (50-70% of maximum heart rate), spread over ≥days/week, and 3) resistance 
training at least twice per week (unless contraindicated) in all adults with DM.21 The evidence on the 
benefits of exercise in individuals with T2DM was reviewed by a joint statement from the ADA and 
American College of Sports Medicine.188 
As in non-diabetics, cigarette smoking can cause numerous deleterious effects in patients with 
DM such as impaired glycemic control, abnormal lipid profile and increased risk of CV morbidity and 
mortality.189–191 Smoking has also been linked to significantly increased risk of DM.192 Unsurprisingly, 
smoking cessation leads to many favorable outcomes in patients with DM such as favorable lipid profile 
and decreased risk of mortality.191,193 ADA strongly recommends smoking cessation in patients with 
DM.21 One concern about smoking cessation in patients with prediabetes or T2DM have been the risk of 
weight gain and associated worsening of the glycemic profile after quitting. Some studies have 
demonstrated an increased short-term risk of impaired fasting glucose or T2DM after quitting 
smoking.194,195 But the risk decreases as the time from smoking cessation increases.192 It is 
recommended that, in at-risk populations, smoking cessation should be supported by lifestyle 
interventions to prevent weight gain and development of T2DM.194 A recent meta-analysis of 14 
observational studies with a total of >98,000 participants with T1DM and T2DM demonstrated no 
significant long-term change in HbA1c levels due to quitting.191  
Antiplatelet Therapy for Primary Prevention 
Antiplatelet therapy is a fundamental component of secondary prevention of CV events in 
diabetic and non-diabetic patients with a history ASCVD. However, the clinical utility of antiplatelet 
therapy for primary prevention of CV events in patients with no known ASCVD is controversial.196 Aspirin 
use in patients with T2DM results in improvement in biomarkers of CV risk such as high sensitivity C-
reactive protein, adiponectin, tumor necrosis factor-α, interleukin-1β, myeloperoxidase, and soluble 
CD40 ligand.197 Several RCTs assessed the efficacy and safety of aspirin for primary CVD prevention in 
patients with DM. However, they failed to consistently show a signiﬁcant reduction in overall ASCVD end 
points with the use of aspirin. A landmark meta-analysis was published in 2009 and included six primary 
prevention trials with a combined sample size of 95,000 individuals from the general population.198 The 
analysis demonstrated a 12% statistically significant reduction in the composite of serious CV events 
(vascular death, MI, or stroke) with the use of aspirin. People with diabetes in this meta-analysis 
(n=4000) had a similar (12%) but the non-significant relative reduction of serious vascular events with 
aspirin. A recent meta-analysis which specifically included subjects with DM (from 10 different primary 
prevention trials) demonstrated that aspirin was associated with 10% reduction of all serious CV events, 
but no statistically significant difference in MI and stroke rates.199 Aspirin use, even low dose, for 
primary prevention in patients with DM have been linked to increased bleeding complications.200,201 
Therefore, the net benefit of aspirin for primary prevention in patients with DM depends on the baseline 
risks for CVD and bleeding.15  
A significant variation exists among major society guidelines in regards to the use of aspirin for 
primary prevention in diabetic populations. The most recent guidelines from European Society of 
Cardiology on prevention of CVD recommended against routine use of aspirin for primary prevention in 
patients with DM unless they have overt CVD.202 A scientific statement from the ADA and AHA 
concluded that low-dose aspirin (75-162 mg/day) is reasonable for primary prevention in adults with DM 
at high risk (10-year CVD risk >10%) and without an increased risk of bleeding.15 This includes most 
patients with type-1 or type-2 DM aged ≥50 years who have at least one additional CV risk factor such as 
HTN, smoking, dyslipidemia, albuminuria and family history of premature ASCVD.21   
Glycemic Control for Prevention of Heart Disease 
Glycemic Control in Type 2 Diabetes Mellitus 
CVD risk correlates with plasma glucose levels even below the definition of overt diabetes.203,204 
In a large prospective cohort study with nearly 19,000 participants (normoglycemic, prediabetic or 
diabetic) from 21 different countries, every 1 mmol/L (18 mg/dL) increase in FPG was associated with 
17% increase in the risk of future CV morbidity and mortality.205 Similarly, every 1% increment in HbA1c 
was found to predict 18% higher risk of CV events and 19% higher risk of MI.206,207 Hyperglycemia shows 
much stronger correlation with microvascular complications compared to that with macrovascular 
complications. For instance, every 1% increase in HbA1c was associated with 37% increase in the risk of 
diabetic nephropathy and retinopathy.208 
Intensive glycemic control has consistently been linked to lower risk and severity of 
microvascular complications in patients with T2DM.209 However, the effects of intensified glucose 
lowering on the rate of macrovascular complications remain controversial. Several major RCTs have 
evaluated the impact of intensive blood glucose control on CV events in patients with T2DM. In the 
UKPDS study, published two decades ago (n=3867 T2DM patients and ~10 years follow-up), intensive 
blood glucose control with sulfonylurea or insulin did not lead to a significant change in the MI 
frequency despite a 0.9% (7.9% vs. 7.0%) lower HbA1c level in the intensive control group.209 A post-trial 
follow-up report of UKPDS study revealed that patients assigned to the intensive blood glucose control 
during the study period had a lower rate of microvascular complications, myocardial infarction, and all-
cause mortality after ten years of follow-up.210 It is interesting that this difference was present despite 
an early loss of glycemic differences between intensive and standard blood glucose control groups after 
completion of the original trial.  
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (n=10251 and ~3.5 years 
follow-up) compared an intensive glucose strategy (achieved HbA1c 6.4%) with standard therapy 
(achieved HbA1c goal of 7.5%) in patients with T2DM who had a high risk of CVD. The study found 
increased mortality in the intensive arm, and this was driven mainly by CV mortality.211 The ADVANCE 
(Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled 
Evaluation) trial evaluated the prognostic effects of intensive glucose lowering and routine BP control in 
>11.000 patients with T2DM.
212,213
 Compared to standard blood glucose lowering (<HbA1c of 7.3%), 
intensive lowering (<HbA1c of 6.5%) was linked to a significant reduction in the microvascular events but 
no change in the rate of macrovascular events. The VADT (Veterans Affairs Diabetes Trial) which 
included 1791 patients with T2DM revealed a significant reduction in major CV events in response to 
intensive blood glucose control.
214
 However, no significant change was observed in overall mortality. The 
ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial (n=12537, follow-up >6 years) 
examined the prognostic effect of the early use of insulin glargine for a target FPG level of <95 mg/dl in 
patients with increased CV risk in addition to pre-diabetes or early T2DM. Compared to the standard 
care, early use of insulin glargine and associated lower FPG levels did not lead to any improvement or 
worsening of CV outcomes.215,216 
Recent RCTs have demonstrated significant improvement in CV outcomes with some of the 
relatively novel antidiabetic agents. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors exert their 
glucose-lowering effects by decreasing renal reabsorption of glucose. Empagliflozin, dapagliflozin and 
canagliflozin are the SGLT-2 inhibitors in the market. In addition to their antidiabetic effects, SGLT-2 
inhibitors have been shown to increase diuresis and reduce weight, glomerular filtration rate, albuminuria, 
and systolic and diastolic BP.
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 The effect of Empagliflozin on CV outcomes was evaluated in the EMPA-
REG OUTCOME trial which included >7000 patients with a history of T2DM and CVD.
218
 After a median 
of 3.1-years follow-up, empagliflozin was associated with >30% relative risk reduction of CV mortality, HF 
hospitalization, and all-cause mortality when compared with placebo in addition to standard care. 
Currently, it remains unclear which mechanisms are most responsible for the marked CV risk reduction 
with use of Empagliflozin.
217
 It is also not known whether Empagliflozin would have the similar protective 
effect in individuals who do not have ASCVD but at high risk for it.  
Glucagon-like peptide-1 (GLP-1) agonists (i.e. liraglutide, semaglutide, exenatide) are a group of 
parenteral antidiabetic agents which improve glucose homeostasis by enhancing the endogenous 
secretion of insulin induced by meal ingestion and inhibiting glucagon secretion.
219
 The LEADER 
(Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial examined 
the CV prognostic impact of Liraglutide in >9300 T2DM patients with either known CVD (age 50 to 60 
years) or age of  60 years with additional CV risk factor(s).220 The investigators found a significant 
reduction in the rate of the first occurrence of non-fatal MI, non-fatal stroke, and death from CVD with the 
use of Liraglutide compared to placebo in addition to standard care. Similar improved CV outcomes were 
demonstrated with another GLP-1 agonist, semaglutide, in an RCT with a relatively smaller sample size 
(n=2735).
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 Though, it should be noted that this study was powered as a non-inferiority study rather than 
superiority.   
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a group of oral antidiabetic agents which reduce 
blood glucose by enhancing pancreatic insulin secretion and suppressing glucagon secretion.
222
 DPP-4 
inhibitors such as Saxagliptin, Alogliptin, and Sitagliptin were evaluated in RCTs in regards to their effect 
on CV outcomes. Overall, DPP-4 inhibitors did not increase or decrease the rate of CV events in patients 
with T2DM, except an increase in HF hospitalizations with use of Saxagliptin.
222–225 
Glycemic Control in Type 1 Diabetes Mellitus 
It has been well-established in T1DM patients that intensive blood glucose control leads to a 
reduction in microvascular complications such as nephropathy, retinopathy, neuropathy, retinopathy, 
etc.226 Several observational and few RCTs have revealed that tight blood glucose control can improve 
CV outcomes in patients with T1DM. The Diabetes Control and Complications Trial (DCCT), conducted 
between 1993 and 2003 and included 1441 patients with T1DM who were randomized to standard or 
intensive glucose control strategies for a mean duration of 6.5 years (mean follow-up of 17 years).227 The 
study demonstrated 42% relative reduction in CV events and 57% relative reduction in nonfatal MI, 
stroke or death from CVD with intensive blood glucose control. A more recently published long-term 
follow-up of analysis of DCCT found that ~6.5 years of intensive glucose control strategy at the beginning 
of the study period predicted less coronary artery calcification, thinner carotid intima-media thickness 
and lower risk of CV events and cardiac and all-cause mortality (Figure 6).228,229  
An observational study with ~7500 patients with T1DM showed that each 1% increment in 
HbA1c resulted in 31-34% higher risk of CAD and 26-32% higher risk of CVD.230 A nationwide registry 
data from Sweden which included nearly 34,000 patients with T1DM and nearly 170,000 non-diabetic 
controls examined the association between HbA1c levels and risk of mortality.231 The investigators 
found that, compared to non-diabetic controls, T1DM patients with had significantly higher risk of all-
cause and CV mortality, even if the HbA1c levels were tightly controlled. Moreover, the risk of all-cause 
and CV mortality in T1DM patients rose in parallel to HbA1c levels.  
Continuous insulin infusion with pump therapy in T1DM has been linked to fewer episodes of 
hyperglycemia and hypoglycemia compared to multiple daily injections.232 An observational study 
utilizing the data from the Swedish National Diabetes Register found that, compared to multiple daily 
injections, insulin pump therapy led to 42% reduction in CV mortality and 27% reduction in all-cause 
mortality.233 We still need well-designed RCTs to examine the CV benefits of insulin pump therapy. 
Albuminuria, Diabetic Kidney Disease, and Cardiovascular Prevention 
Diabetic kidney disease (DKD) is a common complication of T1DM and T2DM. DKD can present 
with albuminuria, impaired GFR or both. Microalbuminuria, usually the earliest manifestation of DKD, is 
defined as 24-hour urinary albumin excretion rate of 30 to 299 mg. Macroalbuminuria refers to albumin 
excretion rate of 300 mg/24-hours.17 Epidemiologic studies demonstrated a strong correlation 
between risk of all-cause mortality and severity of DKD, from microalbuminuria to macroalbuminuria to 
ESRD.234 The HOPE (Heart Outcomes Prevention Evaluation) study showed that presence of 
microalbuminuria significantly increases the future risk of CV events, HF hospitalizations and all-cause 
mortality in individuals with and without diabetes (Figure 7).235 In the ROADMAP (Randomized 
Olmesartan and Diabetes Microalbuminuria Prevention) study, which included >1700 patients with 
T2DM and normoalbuminuria at baseline, development of microalbuminuria over time was associated 
with 80% increase in the risk of CV events.236 Data from the LIFE (Losartan Intervention for Endpoint 
Reduction) study, which included diabetic and non-diabetic subjects, demonstrated that every 10-fold 
increment in the urinary albumin to creatinine ratio resulted in 45%, 51%, and 98% increase in the risk of 
MI, stroke, and CV mortality, respectively.237   
In conclusion, albuminuria screening carries significance for CVD prevention in diabetic 
individuals, since it can help with CV risk stratification and identification of individuals at risk for CVD. 
ACE inhibitors and ARBs are the cornerstone of management albuminuria in patients with DM. 
Independent of their BP reducing effect, these drugs can delay, prevent and reduce albuminuria.236 Data 
from RENAAL (Reduction in Endpoints in Non-insulin-dependent DM with the Angiotensin II Antagonist 
Losartan) trial, an RCT which included T2DM patients with nephropathy, revealed that every 50% 
reduction of albuminuria in the first-6 months resulted in 18% reduction in CVD risk and 27% in HF 
risk.238 Another RCT in patients with T2DM and HTN (n=393) demonstrated that change in the urinary 
albumin excretion over time was a strong independent predictor of CV mortality,  and the reduction in 
urinary albumin excretion across all albuminuria categories (normo-, micro-, macro-) was an 
independent predictor of improved long-term survival.239  
CONCLUSIONS 
DM has become a public health problem worldwide. The rise in the global prevalence of DM has been 
attributed to obesity, dietary patterns, and sedentary lifestyle. DM is a major independent risk factor for 
CVD. Increased CVD risk in DM is caused by a complex interplay between numerous pathophysiologic 
mechanisms. DM and CVD share several common mechanisms which play a role in the development of 
both conditions. Abnormalities of glucose homeostasis, even at the pre-diabetes stage, can trigger 
several alterations in the CV structure and function. Patients with DM commonly have comorbidities (i.e. 
HTN, hyperlipidemia, and chronic kidney disease) which further augment the risk of CVD. Moreover, the 
CVD risk in diabetic patients is significantly modified by a variety of genetic and epigenetic factors. 
Research in the recent decades has broadened our knowledge on the pathogenesis of CVD in patients 
with DM, and this progress raises hope for more effective modalities for prevention of CVD in patients 
with DM. Prevention of heart disease in diabetic patients usually requires a multidisciplinary approach 
and active cooperation by the patients. The key components of prevention efforts include lifestyle 
modification, weight loss, and management of co-morbidities such as HTN, dyslipidemia, albuminuria, 
etc. The CV benefits of intensified glycemic control remain controversial in patients with T2DM. Some 
relatively novel antidiabetic agents, such as Empagliflozin and Liraglutide, have emerged with their CV 
protective effects supported by RCTs. Available evidence suggests that tight blood glucose control is 
effective in the prevention of macrovascular complications in patients with T1DM.   
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TABLE / FIGURE LEGENDS 
Table 1: 
Title: Guideline / scientific statement recommendations on target blood pressure levels in diabetic 
individuals 
Caption: *Individuals with chronic kidney disease, urine albumin excretion <30 mg/day. **Individuals 
with chronic kidney disease, urine albumin excretion 30 mg/day. DBP, diastolic blood pressure; SBP, 
systolic blood pressure 
 
Table 2: 
Title: Recommendations from the American Diabetes Association for statin and combination treatment 
in patients with diabetes 
Caption: Adapted from the ‘Standards of Medical Care in Diabetes-2017’ report.21 *In addition to 
intensive lifestyle therapy. **ASCVD risk factors include hypertension, smoking, chronic kidney disease, 
albuminuria, family history of premature ASCVD, and LDL cholesterol     mg/dL. ***High intensity of 
individuals age 40-75 years. ASCVD, atherosclerotic cardiovascular disease. 
 
Table 3: 
Title: Antidiabetic agents by their weight effects 
 
Figure 1: 
Title:  Trends in the prevalence of diabetes mellitus among US adults (≥20 years of age) 
Caption: Age-standardized US trends in total-, diagnosed-, and undiagnosed diabetes based on the data 
from National Hearth and Nutrition Examination Survey. Diagnosed diabetes was defined by self-report 
of a previous diagnosis of diabetes. Undiagnosed diabetes was defined by a hemoglobin A1c ≥6.5% or 
fasting plasma glucose ≥126 mg/dL despite having no prior diagnosis of diabetes. Error bars indicate 95% 
confidence intervals. Reproduced from Menke et al. with permission from the publisher.2  
 
Figure 2: 
Caption: Proportion of individuals with incidental CAD according to baseline insulin resistance levels and 
glycemic progression over four years (n=2076 non-diabetic participants at baseline). Reproduced from 
Rhee et al. with permission from the publisher.31 CAC, coronary artery calcification; IFG, impaired fasting 
glucose; HOMA-IR, homeostasis model assessment-insulin resistance. 
 
Figure 3: 
Title: Cumulative hazard rate of recurrence of CVD according to the stages CAN in patients with type 2 
diabetes mellitus  
Caption: Reproduced from Cha et al. (open-access).78 The investigators examined the relationship 
between CAN and recurrent CVD in in a prospective cohort of 206 patients with type 2 diabetes and 
history of CVD. Cardiovascular autonomic function test was used to evaluate for CAN. In the 
multivariable model, compared to patients with no CAN, those with early and definite CAN had 2- and 3-
fold higher risk of CAN, respectively.  CAN, cardiovascular autonomic dysfunction; CV, cardiovascular 
disease.  
 
Figure 4: 
Title: Relative risk of coronary heart disease according to diabetes status and haptoglobin genotype 
Caption: Multivariate analysis of data from two different cohorts evaluating the joint effects of HbA1c 
level and Hp genotype on the relative risk of coronary heart disease. HbA1c, hemoglobin A1c; Hp, 
haptoglobin; RR, relative risk. Reproduced from Cahill et al. with permission from the publisher.85 
 Figure 5: 
Title: Pathogenesis of diabetic cardiomyopathy 
Caption: SNS, sympathetic nervous system; RAAS, renin-angiotensin-aldosterone system. Reproduced 
from Jia et al. with permission from the publisher.125 
 
 
Figure 6:  
Title:  Cumulative incidence of mortality by glycemic control strategy in the Diabetes Control and 
Complications Trial (DCCT) 
Caption: Intent-to-treat analysis for the intensive vs. conventional treatment groups using the data from 
the DCCT (1983-1993) and the subsequent observational follow-up Epidemiology Diabetes Interventions 
and Complications study. HR, hazard ratio; y, year. Reproduced from Orchard et al. with permission from 
the publisher.229  
 
 
Figure 7:  
Title:  Relative risk of cardiovascular outcomes according to the quartiles of albuminuria in diabetic 
individuals 
Caption: Relative risk of cardiovascular (CV) outcomes in reference to the first quartile in the diabetic 
participants of the Heart Outcomes Prevention Evaluation (HOPE) Study. CV events include myocardial 
infarction, stroke, and CV death. P for trend was <0.001 for each CV outcome after adjusting for age, 
sex, systolic and diastolic blood pressure, hemoglobin A1c, waist-to-hip ration.  CHF, congestive heart 
failure. The figure was drawn based on data from Gerstein et al..235  
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Guideline 
Target SBP 
(mm Hg) 
Target DBP 
(mm Hg) 
Publication 
Year 
8th Joint National Committee 140 90 2014 
American Diabetes Association 140 90 2017 
American Society of Hypertension / 
International Society of Hypertension 
140 90 2014 
European Society of Hypertension 140 85 2013 
Canadian Hypertension Education Program 130 80 2016 
British Hypertension Society / National 
Institute for Health and Care Excellence 
140 90 2013 
National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative* 
140 90 2012 
National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative** 
130 80 2012 
 
Age Group Risk Factors 
Intensity of 
Statin Therapy* 
<40 years 
None None 
ASCVD risk factor(s)** Moderate or high 
ASCVD High 
≥40 years 
None Moderate 
ASCVD risk factor(s) Moderate or high*** 
ASCVD High 
ACS and LDL cholesterol ≥50 
mg/dL or history of ASCVD with 
intolerance to high-dose statins 
Moderate plus 
ezetimibe 
 
 
 
 
Weight Loss 
 Metformin 
 α-glucosidase inhibitors 
 Glucagon-like peptide 1 agonists 
 Amylin mimetics 
 Sodium-glucose cotransporter 2 inhibitors 
Weight Gain 
 Insulin secretagouges 
 Thiazolidinediones 
 Insulin 
Weight Neutral  Dipeptidyl peptidase 4 inhibitors 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
